PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

NUCKS nuclear elevated expression indicates progression and prognosis of ovarian cancer.

Abstract NUCKS (nuclear, casein kinase, and cyclin-dependent kinase substrate) is implicated in the tumorigenesis of several human malignancies, but its role in ovarian cancer remains unknown. We aim to investigate NUCKS expression and its clinical significance in ovarian cancer. The messenger RNA expression of NUCKS was determined in normal and malignant ovarian tissues using quantitative polymerase chain reaction assay. Immunohistochemistry was applied to detect the status of NUCKS protein expression in 121 ovarian cancer tissues. NUCKS protein high expression was detected in 52 (43.0%) of 121 patients. NUCKS messenger RNA expression was gradually upregulated in non-metastatic ovarian cancers ( n = 20), metastatic ovarian cancers ( n = 20), and its matched metastatic lesions ( n = 20) in comparison with that in normal ovarian tissues ( n = 10; p < 0.05). Elevated expression of NUCKS in ovarian cancer was associated significantly with the Federation of Gynecology and Obstetrics stage ( p = 0.037), histological grade ( p = 0.003), residual disease ( p = 0.013), lymph node metastasis ( p = 0.002), response to chemotherapy ( p < 0.001), and recurrence ( p = 0.013). In the multivariate Cox analysis, NUCKS expression was an independent prognostic marker for overall survival and disease-free survival in ovarian cancer with p values of <0.001 for both. Especially, NUCKS overexpression had prognostic potential for overall survival and disease-free survival ( p < 0.001 for both) in advanced ovarian cancers and only for disease-free survival in early ovarian cancers ( p = 0.017). Our data suggest that NUCKS overexpression may contribute to progression and poor prognosis in ovarian cancer especially in advanced ovarian cancer.
PMID
Related Publications

High expressions of BCL6 and Lewis y antigen are correlated with high tumor burden and poor prognosis in epithelial ovarian cancer.

Thymidine kinase 1 expression in ovarian serous adenocarcinoma is superior to Ki-67: A new prognostic biomarker.

Effect of NUCKS-1 overexpression on cytokine profiling in obese women with breast cancer.

Increased NUCKS expression is a risk factor for poor prognosis and recurrence in endometrial cancer.

Upregulation of centrosomal protein 55 is associated with unfavorable prognosis and tumor invasion in epithelial ovarian carcinoma.

Authors

Mayor MeshTerms

Prognosis

Keywords

NUCKS

Ovarian cancer

lymph node metastasis

prognosis

resistance

Journal Title tumour biology : the journal of the international society for oncodevelopmental biology and medicine
Publication Year Start




PMID- 28877654
OWN - NLM
STAT- MEDLINE
DA  - 20170907
DCOM- 20170912
LR  - 20170912
IS  - 1423-0380 (Electronic)
IS  - 1010-4283 (Linking)
VI  - 39
IP  - 9
DP  - 2017 Sep
TI  - NUCKS nuclear elevated expression indicates progression and prognosis of ovarian 
      cancer.
PG  - 1010428317714631
LID - 10.1177/1010428317714631 [doi]
AB  - NUCKS (nuclear, casein kinase, and cyclin-dependent kinase substrate) is
      implicated in the tumorigenesis of several human malignancies, but its role in
      ovarian cancer remains unknown. We aim to investigate NUCKS expression and its
      clinical significance in ovarian cancer. The messenger RNA expression of NUCKS
      was determined in normal and malignant ovarian tissues using quantitative
      polymerase chain reaction assay. Immunohistochemistry was applied to detect the
      status of NUCKS protein expression in 121 ovarian cancer tissues. NUCKS protein
      high expression was detected in 52 (43.0%) of 121 patients. NUCKS messenger RNA
      expression was gradually upregulated in non-metastatic ovarian cancers ( n = 20),
      metastatic ovarian cancers ( n = 20), and its matched metastatic lesions ( n =
      20) in comparison with that in normal ovarian tissues ( n = 10; p &lt; 0.05).
      Elevated expression of NUCKS in ovarian cancer was associated significantly with 
      the Federation of Gynecology and Obstetrics stage ( p = 0.037), histological
      grade ( p = 0.003), residual disease ( p = 0.013), lymph node metastasis ( p =
      0.002), response to chemotherapy ( p &lt; 0.001), and recurrence ( p = 0.013). In
      the multivariate Cox analysis, NUCKS expression was an independent prognostic
      marker for overall survival and disease-free survival in ovarian cancer with p
      values of &lt;0.001 for both. Especially, NUCKS overexpression had prognostic
      potential for overall survival and disease-free survival ( p &lt; 0.001 for both) in
      advanced ovarian cancers and only for disease-free survival in early ovarian
      cancers ( p = 0.017). Our data suggest that NUCKS overexpression may contribute
      to progression and poor prognosis in ovarian cancer especially in advanced
      ovarian cancer.
FAU - Shi, Ce
AU  - Shi C
AD  - 1 Department of Leukemia, The First Affiliated Hospital of Harbin Medical
      University, Harbin, China.
FAU - Qin, Ling
AU  - Qin L
AD  - 2 Department of Pathology, Harbin Medical University Cancer Hospital, Harbin,
      China.
FAU - Gao, Hongyu
AU  - Gao H
AD  - 3 Department of Gastroenterologic Surgery, Harbin Medical University Cancer
      Hospital, Harbin, China.
FAU - Gu, Lina
AU  - Gu L
AD  - 4 Department of Gynecology, Harbin Medical University Cancer Hospital, Harbin,
      China.
FAU - Yang, Chang
AU  - Yang C
AD  - 4 Department of Gynecology, Harbin Medical University Cancer Hospital, Harbin,
      China.
FAU - Liu, Hebing
AU  - Liu H
AD  - 5 Department of Biostatistics, School of Medicine, Virginia Commonwealth
      University, Richmond, VA, USA.
FAU - Liu, Tianbo
AU  - Liu T
AD  - 4 Department of Gynecology, Harbin Medical University Cancer Hospital, Harbin,
      China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Tumour Biol
JT  - Tumour biology : the journal of the International Society for Oncodevelopmental
      Biology and Medicine
JID - 8409922
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (NUCKS protein, human)
RN  - 0 (Nuclear Proteins)
RN  - 0 (Phosphoproteins)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers, Tumor/biosynthesis/*genetics
MH  - Disease-Free Survival
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Lymphatic Metastasis
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Nuclear Proteins/biosynthesis/*genetics
MH  - Ovarian Neoplasms/*genetics/pathology
MH  - Phosphoproteins/biosynthesis/*genetics
MH  - Pregnancy
MH  - *Prognosis
OTO - NOTNLM
OT  - NUCKS
OT  - Ovarian cancer
OT  - lymph node metastasis
OT  - prognosis
OT  - resistance
EDAT- 2017/09/08 06:00
MHDA- 2017/09/13 06:00
CRDT- 2017/09/08 06:00
AID - 10.1177/1010428317714631 [doi]
PST - ppublish
SO  - Tumour Biol. 2017 Sep;39(9):1010428317714631. doi: 10.1177/1010428317714631.